|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide)显示文摘 | Boritzki T J Berry D A Besserer J A | | 0，，07： | 1 |
| 2 | Nolaterex, a novel lipophilic thymidylate synthase inhibitor: in vitro and vivo preclinical studies显示文摘 | Bartlett CA Boritzki T J | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 3 | AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and vivo preclinical studies 显示文摘 | Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 4 | AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies 显示文摘 | Webber S Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 5 | An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint显示文摘 | Zhang CC Boritzki TJ Jackson RC | 1998 | Cancer Chemother Pharmacol1998，41，3： | 1 |
| 6 | AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies显示文摘 | BARTLETT CA BORITZKI TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 7 | AG337, a novellipophilic thymidylate synthase inhibitor: in vitro and in vivopreclinical studies显示文摘 | Webber S Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 8 | AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies显示文摘 | Webber S Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 9 | AG337,a novel lipophilic thymidylate synthase inhibitor:in vitro and in vivo preclinical studies显示文摘 | Webber S Bartlett CA Boritzki TJ | | 0，，06： | 1 |
| 10 | Studies on the biochemical mechanism of the novel antitumor agent,CI-920显示文摘 | Fry DW Boritzki TJ Jackson RC | 1984 | Cancer Chemotherapy and Phar-macology1984，13，17： | 1 |
| 11 | AG337,a novel lipophilic thymidylate synthase inhibitors:in vitro and in vivo preclinical studies显示文摘 | Webber S Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，： | 1 |
| 12 | 查看详情显示文摘 | Boritzki T J Berry D A Besserer J A | | 0，，07： | 1 |
| 13 | AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vi- vo preclinical studies显示文摘 | WEBBER S BARTLETT CA BORITZKI TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
| 14 | Inhibition of type Ⅱtopoisomerase by fostriecin显示文摘 | Boritzki TJ Wolfard TS Besserer JA | 1988 | Biochem Pharmacol1988，37，： | 1 |
| 15 | AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies 显示文摘 | Webber S Bartlett CA Boritzki TJ | 1996 | Cancer Chemother Pharmacol1996，37，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员